PMID- 35212658
OWN - NLM
STAT- MEDLINE
DCOM- 20220301
LR  - 20220301
IS  - 1550-5111 (Electronic)
IS  - 0887-9303 (Linking)
VI  - 45
IP  - 2
DP  - 2022 Apr-Jun 01
TI  - SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.
PG  - 189-198
LID - 10.1097/CNQ.0000000000000401 [doi]
AB  - Sodium-glucose cotransporter-2 (SGLT-2) inhibitors (empagliflozin, canagliflozin, 
      dapagliflozin, and ertugliflozin) are a new class of heart failure medications 
      that have previously been exclusively utilized in the management of type 2 
      diabetes mellitus (T2DM). The rationale for using SGLT-2 inhibitors in patients 
      with heart failure has stemmed from recent landmark clinical trials in T2DM in 
      which reductions in mortality and hospitalization for heart failure were first 
      observed. On the basis of these robust outcomes, empagliflozin has further been 
      evaluated in heart failure with reduced ejection fraction (HFrEF) and preserved 
      ejection fraction and dapagliflozin solely in the management of HFrEF. While 
      cardiovascular outcomes among each agent vary depending on the patient 
      population, updates among both the American and European guidelines have included 
      SGLT-2 inhibitors as pillars of therapy. The exact mechanisms for how SGLT-2 
      inhibitors are beneficial in heart failure are unknown, but current hypotheses 
      include multiple metabolic and hemodynamic mechanisms. The purpose of this review 
      is to summarize available literature focusing on the use of the SGLT-2 inhibitors 
      as adjunctive therapy in heart failure, as well as evaluate mechanisms for heart 
      failure benefit, adverse effects, and practical considerations for using these 
      agents in the clinical setting.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - March, Katherine L
AU  - March KL
AD  - Clinical Pharmacy Department, Methodist University Hospital, Memphis, Tennessee 
      (Drs March, Lukas, and Cave); University of Tennessee Health Science Center, 
      College of Pharmacy, Memphis (Drs March, Lukas, and Cave); and University of 
      Wisconsin Hospitals and Clinics, Madison (Drs Berei and Shah).
FAU - Lukas, Jack G
AU  - Lukas JG
FAU - Berei, Theodore J
AU  - Berei TJ
FAU - Shah, Samarth P
AU  - Shah SP
FAU - Cave, Brandon E
AU  - Cave BE
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Crit Care Nurs Q
JT  - Critical care nursing quarterly
JID - 8704517
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Stroke Volume
MH  - United States
COIS- Dr Cave has served on the speaker's bureau for AstraZeneca and Alexion 
      Pharmaceuticals and as a consultant for Novartis Pharmaceuticals. All other 
      authors have no conflicts of interest to disclose.
EDAT- 2022/02/26 06:00
MHDA- 2022/03/03 06:00
CRDT- 2022/02/25 12:22
PHST- 2022/02/25 12:22 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/03/03 06:00 [medline]
AID - 00002727-202204000-00009 [pii]
AID - 10.1097/CNQ.0000000000000401 [doi]
PST - ppublish
SO  - Crit Care Nurs Q. 2022 Apr-Jun 01;45(2):189-198. doi: 
      10.1097/CNQ.0000000000000401.